Outcomes at 90 days showed no substantial differences in mortality or readmission, though researchers say small differences could be clinically relevant.
Accelerated approval granted to Wegovy for treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis in adults with stage F2 to F3 fibrosis.